This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.
To counteract the onslaught from these biosimilars, Roche has prepped filings for a fixed-dose combination of both Herceptin and its other antibody blockbuster Perjeta (pertuzumab), promising simpler dosing of the ... minutes. Currently, Herceptin and
Drugs added include AbbVie's Humira and Roche's Perjeta. Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average ... The key drugs which have been added to the list include
Herceptin plus Xeloda is a standard regimen for HER2-positive breast cancer in patients previously treated with Herceptin and Roche’s other HER2-targeting drugs Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab
Although it has crossed the blockbuster threshold this year, Kadcyla is still the runt of Roche’s HER2 litter lagging well behind Herceptin (trastuzumab) and Perjeta (pertuzumab) in sales terms. ... in order to move it into earlier lines of treatment
According to the Swiss pharma, the key drivers of this growth were mutliple sclerosis medicine Ocrevus, new haemophilia treatment Hemlibra and its cancer medicines – Tecentriq, Perjeta and Avastin. ... The sales increase in US stood at 14%, led by
sales. Not-so-lucky was Roche’s Perjeta (pertuzumab), which has been handed a rejection by the SMC. ... Perjeta has patent protection until 2023 in Europe and 2024 in the US, so Roche will be hoping to continue to push the drug into new areas and
More from news
Approximately 20 fully matching, plus 49 partially matching documents found.
cancer drug Perjeta.
In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Genentech’s Perjeta (pertuzumab). due to lack of sufficient evidence to demonstrate a clinically meaningful overall survival benefit in early-stage disease.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...